Join the Oncology Voice Network. Join for Free
The KOL Model Is Built for Relationships. It Should Be Built for Influence.

The KOL Model Is Built for Relationships. It Should Be Built for Influence.


Share This Article


Summary

The industry invests heavily in KOL relationships — but rarely measures whether those relationships actually influence clinical practice.

The KOL Model Is Built for Relationships. It Should Be Built for Influence.

One Idea Worth Acting On.

A Medical Affairs team maps its KOL universe. Tier 1, Tier 2, Tier 3.

Call frequency targets are set. Engagement metrics are tracked. Advisory board rosters are populated.

The annual KOL plan is presented to leadership. Every box is checked.

And yet the clinical narrative the company needs to land — in guidelines, in prescribing behavior, in payer thinking — is not moving.

The KOL program measured relationship maintenance. It never measured scientific influence. The KOL who attends the advisory board, receives the data package, and leaves without a clear scientific narrative to carry back to their institution is not an asset. They are an opportunity cost.

What's Actually Happening

The KOL model in most oncology organizations is built around access. Identify the physicians with the largest networks and the most prominent platforms. Maintain regular contact. Invite them to advisory boards. Feature them at symposia. Track the interactions.

What the model rarely asks is whether the KOL's engagement is actually changing anything — whether their conversations with peers are shifting clinical thinking, whether their congress presentations are landing the company's scientific narrative, whether their guideline committee participation is informed by the data the company most needs them to understand.

As Dr. Robin Winter-Sperry, pharmaceutical industry strategist and contributor to Voices of Oncology, describes it: the difference between a KOL who is engaged and a KOL who is influential is the difference between someone who attends your advisory board and someone who changes how their colleagues think. The first is easy to measure. The second is what the organization actually needs.

The KOL program produces the metric it is designed to produce. If the metric is relationship activity, it produces relationship activity. If the metric is scientific influence — clinical practice change, guideline adoption, prescriber behavior shift — it produces something else entirely. Most programs are measuring the first and hoping for the second.

Why This Matters

In oncology, clinical practice is shaped by a small number of opinion leaders whose scientific credibility gives them disproportionate influence over how the broader community interprets data, adopts new therapies, and updates practice patterns.

When the KOL program is managed as a relationship maintenance function rather than a scientific influence function, organizations invest heavily in access to the right people and invest almost nothing in ensuring those people have what they need to actually influence clinical practice on the company's behalf.

The KOL who attends the advisory board, receives the data package, and leaves without a clear scientific narrative to carry back to their institution is not an asset. They are an opportunity cost.

Where It Breaks in the Real World

A company invests in a tier-1 KOL program for its newly approved oncology therapy. Eighteen KOLs. Quarterly advisory boards. Congress symposia. Regional speaker programs.

Twelve months after launch, market research reveals that the scientific narrative the company built — the specific clinical positioning that distinguishes the therapy from its competitors — is not the narrative the KOLs are carrying in their peer conversations. They are describing the drug accurately. They are not describing it in the way that would differentiate it.

The access was there. The scientific alignment was not built. The KOL program maintained relationships and failed to transfer the clinical narrative.

What Needs to Change

KOL engagement needs to be measured at the outcome level — not whether the interaction occurred, but whether the KOL left with a scientific narrative they can use, whether they used it, and whether their use of it moved clinical thinking in the direction the evidence supports.

That requires a different kind of KOL interaction. Not advisory boards designed to collect feedback and validate strategy. Scientific exchanges designed to equip the KOL with the specific data, the specific framing, and the specific answers to the specific objections they will encounter in their peer conversations.

The organizations getting this right are not managing more KOL relationships. They are investing more deeply in fewer of them.

The Bottom Line

A KOL who has been engaged is not the same as a KOL who can move clinical practice.

Until KOL programs are measured on scientific influence rather than relationship activity, the investment will keep producing the metric it is asked for — and missing the outcome the organization needs.

Add Your Voice — Where are you seeing this? What's working — and what's not?

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology
OVN Avatar Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Article
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals
OVN Avatar R. Kurzrock, L.A. Gurski, R.W. Carlson, D.S. Ettinger, S.M. Horwitz, S.K. Kumar, L. Million, M. von Mehren, A.B. Benson III

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals

Article
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies
OVN Avatar Barbara Kiesewetter , Nathan I Cherny, Nicolas Boissel, Francesco Cerisoli, Urania Dafni, Elisabeth G E de Vries, Paolo Ghia, Nicola Gökbuget, Verónica González-Calle, Brian Huntly, Ulrich Jäger, Nicola Jane Latino, Jean-Yves Douillard, Luca Malcovati, Ma

EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for hematological malignancies

Article
The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions
OVN Avatar Charles L. Bennett , Sumimasa Nagai , Andrew C. Bennett , Shamia Hoque , Chadi Nabhan , Martin W. Schoen , William J. Hrushesky , Stefano Luminari , Paul Ray , Paul R. Yarnold , Bart Witherspoon , Josh Riente , Laura Bobolts , John Brusk , Rebecca Tombles

The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions

Article
Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms
OVN Avatar Angus Liu

Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms

Article
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
OVN Avatar Yan Ji, Jin Y. Jin, David M. Hyman, Geoffrey Kim and Ajit Suri

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology

Explore OVN